IN2014DN08632A - - Google Patents

Info

Publication number
IN2014DN08632A
IN2014DN08632A IN8632DEN2014A IN2014DN08632A IN 2014DN08632 A IN2014DN08632 A IN 2014DN08632A IN 8632DEN2014 A IN8632DEN2014 A IN 8632DEN2014A IN 2014DN08632 A IN2014DN08632 A IN 2014DN08632A
Authority
IN
India
Prior art keywords
production
during
eye drop
chelating agent
diquafosol
Prior art date
Application number
Other languages
English (en)
Inventor
Akiko Sakatani
Tatsuo Ikei
Koji Inagaki
Masatsugu Nakamura
Kazuhiro Hosoi
Mikiko Saito
Masaki Sonoda
Yoko Fukui
Mitsuaki Kuwano
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49259901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN08632(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of IN2014DN08632A publication Critical patent/IN2014DN08632A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN8632DEN2014 2012-03-26 2013-03-25 IN2014DN08632A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012069157 2012-03-26
PCT/JP2013/058519 WO2013146649A1 (fr) 2012-03-26 2013-03-25 Gouttes oculaires contenant du diquafosol

Publications (1)

Publication Number Publication Date
IN2014DN08632A true IN2014DN08632A (fr) 2015-05-22

Family

ID=49259901

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8632DEN2014 IN2014DN08632A (fr) 2012-03-26 2013-03-25

Country Status (26)

Country Link
US (4) US9486529B2 (fr)
EP (2) EP3431092A1 (fr)
JP (6) JP5625081B2 (fr)
KR (5) KR20190002751A (fr)
CN (2) CN113018259A (fr)
AU (3) AU2013241507A1 (fr)
BR (1) BR112014023402B1 (fr)
CA (1) CA2868390C (fr)
DK (1) DK2832359T3 (fr)
EA (1) EA028848B1 (fr)
ES (1) ES2702575T3 (fr)
GE (1) GEP20166470B (fr)
HK (2) HK1204922A1 (fr)
HU (1) HUE041671T2 (fr)
IN (1) IN2014DN08632A (fr)
MX (1) MX353874B (fr)
MY (1) MY169816A (fr)
NZ (1) NZ631041A (fr)
PH (1) PH12014501955A1 (fr)
PL (1) PL2832359T3 (fr)
PT (1) PT2832359T (fr)
SG (2) SG10201607872PA (fr)
TR (1) TR201820073T4 (fr)
TW (4) TWI692364B (fr)
UA (1) UA113981C2 (fr)
WO (1) WO2013146649A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169816A (en) 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
MX2016009049A (es) 2014-01-10 2016-09-09 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
JP6104433B2 (ja) * 2015-06-05 2017-03-29 参天製薬株式会社 水性点眼液
BR112017013841A2 (pt) * 2014-12-25 2018-06-19 Santen Pharmaceutical Co., Ltd. solução oftálmica aquosa
WO2016195072A1 (fr) * 2015-06-05 2016-12-08 参天製薬株式会社 Agent thérapeutique contre la sécheresse oculaire caractérisé par sa capacité à être instillé sous forme de goutte dans l'oeil de patients souffrant d'une sécheresse oculaire et portant des lentilles de contact souples
JPWO2017002827A1 (ja) 2015-06-29 2018-04-26 ヤマサ醤油株式会社 Ｐ１，ｐ４−ビス（５’−ウリジル）テトラホスフェート結晶の保管方法
JP6688057B2 (ja) * 2015-12-01 2020-04-28 日水製薬株式会社 グラム染色用後染色試液及びグラム染色方法
KR20220163519A (ko) * 2018-02-28 2022-12-09 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 및 양이온성 폴리머를 함유하는 안과용 조성물
CN108403625A (zh) * 2018-04-11 2018-08-17 东莞解石医药科技有限公司 一种含有螯合剂的地夸磷索四钠滴眼液
KR20240049646A (ko) * 2019-08-27 2024-04-16 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
CN113720924A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种地夸磷索四钠的含量及有关物质检测方法
WO2022107791A1 (fr) * 2020-11-18 2022-05-27 参天製薬株式会社 Solution ophtalmique aqueuse contenant un polyhexaméthylène biguanide ou un sel de celui-ci
JPWO2022107790A1 (fr) * 2020-11-18 2022-05-27
KR102548710B1 (ko) 2020-12-24 2023-06-28 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
CN112933040A (zh) * 2021-02-04 2021-06-11 合肥博思科创医药科技有限公司 一种舒更葡糖钠注射液的制备方法
WO2023195718A1 (fr) * 2022-04-04 2023-10-12 서울대학교산학협력단 Composition permettant de supprimer la sucrosité et procédé de suppression de sucrosité d'aliments
CN117838628B (zh) * 2024-03-01 2024-05-28 广州市桐晖药业有限公司 一种地夸磷索钠滴眼液及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH075456B2 (ja) * 1988-10-01 1995-01-25 参天製薬株式会社 点眼液
JP2530491B2 (ja) 1988-12-20 1996-09-04 参天製薬株式会社 ヒアルロン酸点眼液
TW200402B (fr) 1990-08-13 1993-02-21 Senju Pharma Co
US5504113A (en) 1994-03-02 1996-04-02 Allergan, Inc. Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
DK0981534T3 (da) 1997-02-06 2006-09-04 Inspire Pharmaceuticals Inc Dinukleotider og deres anvendelser
BRPI9810436B1 (pt) 1997-07-25 2015-12-29 Inspire Pharmaceuticals Inc processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo
KR19990074047A (ko) 1998-03-03 1999-10-05 김수복 콘택트렌즈용 세척, 소독 및 보존제 조성물
JP5138128B2 (ja) 1998-08-21 2013-02-06 千寿製薬株式会社 水性液剤
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
CA2413928C (fr) 2000-05-30 2011-01-25 Santen Pharmaceutical Co., Ltd. Promoteurs de l'extension de l'epithelium corneen
JP4003008B2 (ja) 2000-05-30 2007-11-07 参天製薬株式会社 角膜上皮伸展促進剤
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US6583181B1 (en) 2000-11-22 2003-06-24 Lonza Inc. Antimicrobial quaternary ammonium compositions with reduced ocular irritation
CN1228053C (zh) * 2001-09-11 2005-11-23 参天制药株式会社 含有二尿苷磷酸的滴眼液
JP2003160491A (ja) * 2001-09-11 2003-06-03 Santen Pharmaceut Co Ltd ジウリジンリン酸含有点眼液
WO2003030892A1 (fr) 2001-10-11 2003-04-17 Alcon, Inc. Methodes de traitement de l'oeil sec
ATE381947T1 (de) 2003-04-14 2008-01-15 Wyeth Corp Zusammensetzungen enthaltend piperacillin und tazobactam zur injektion
JP4806956B2 (ja) 2004-04-20 2011-11-02 大正製薬株式会社 点眼用液剤
US20060073172A1 (en) 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
KR20070067189A (ko) 2004-12-02 2007-06-27 비너스 레머디스 리미티드 주사제에 유용한 베타-락타마제 억제제를 이용한베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
JP4168071B2 (ja) 2005-12-08 2008-10-22 興和株式会社 点眼用組成物
JP2008247828A (ja) 2007-03-30 2008-10-16 Wakamoto Pharmaceut Co Ltd ラタノプロストを含有する水性医薬組成物。
JP2009040727A (ja) * 2007-08-09 2009-02-26 Towa Yakuhin Kk ラタノプロストを有効成分とする安定な点眼液剤
CN100534423C (zh) * 2007-11-30 2009-09-02 张咏梅 一种保质期长的氯霉素滴眼液及其制备方法
US8119112B2 (en) 2008-01-31 2012-02-21 Bausch & Lomb Incorporated Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid
CN101461778A (zh) * 2009-01-06 2009-06-24 河北科技大学 不含抑菌剂的盐酸环丙沙星滴眼液及其制备方法
US20100190734A1 (en) * 2009-01-23 2010-07-29 Romulus Kimbro Brazzell Method of treating dry eye disease with azithromycin
CN102100693A (zh) * 2009-12-16 2011-06-22 沈阳兴齐制药有限公司 一种含有肌肽的人工泪液及其制备方法
KR20110104367A (ko) 2010-03-16 2011-09-22 삼천당제약주식회사 무보존제 안과용 조성물
WO2012012640A1 (fr) 2010-07-21 2012-01-26 Cumberland Pharmaceuticals, Inc. Compositions d'acétylcystéine et méthodes d'utilisation correspondantes
BR112013005438B1 (pt) 2010-09-10 2021-09-21 Santen Pharmaceutical Co., Ltd Agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo
SG10201508591UA (en) 2010-12-28 2015-11-27 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
RU2014143008A (ru) 2012-03-26 2016-05-20 Дилафор Аб Способ лечения остановки родов
MY169816A (en) * 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol

Also Published As

Publication number Publication date
US9486529B2 (en) 2016-11-08
KR20180079469A (ko) 2018-07-10
AU2016201111A1 (en) 2016-03-10
US20180353531A1 (en) 2018-12-13
NZ631041A (en) 2016-10-28
EP2832359A1 (fr) 2015-02-04
HK1204922A1 (en) 2015-12-11
CN104203254A (zh) 2014-12-10
US20170020910A1 (en) 2017-01-26
EP3431092A1 (fr) 2019-01-23
JP7447176B2 (ja) 2024-03-11
SG10201607872PA (en) 2016-11-29
TWI625135B (zh) 2018-06-01
MY169816A (en) 2019-05-16
EP2832359B1 (fr) 2018-11-14
KR20200096708A (ko) 2020-08-12
HK1206648A1 (en) 2016-01-15
US11166974B2 (en) 2021-11-09
EA201491771A1 (ru) 2015-01-30
HUE041671T2 (hu) 2019-05-28
GEP20166470B (en) 2016-04-25
TWI692364B (zh) 2020-05-01
TW201806583A (zh) 2018-03-01
JP5625081B2 (ja) 2014-11-12
KR20190002751A (ko) 2019-01-08
MX2014011468A (es) 2015-01-12
JP6483299B2 (ja) 2019-03-13
PH12014501955B1 (en) 2014-11-17
EA028848B1 (ru) 2018-01-31
BR112014023402B1 (pt) 2020-09-29
CA2868390C (fr) 2020-03-31
KR20150027312A (ko) 2015-03-11
WO2013146649A1 (fr) 2013-10-03
JP2014132039A (ja) 2014-07-17
KR101935484B1 (ko) 2019-01-04
PH12014501955A1 (en) 2014-11-17
US10071113B2 (en) 2018-09-11
JP6389544B2 (ja) 2018-09-12
EP2832359A4 (fr) 2015-03-25
US10632139B2 (en) 2020-04-28
DK2832359T3 (en) 2019-02-04
US20150072951A1 (en) 2015-03-12
CA2868390A1 (fr) 2013-10-03
JP2018076384A (ja) 2018-05-17
JP2019070053A (ja) 2019-05-09
JP2017119718A (ja) 2017-07-06
TWI723722B (zh) 2021-04-01
UA113981C2 (xx) 2017-04-10
TW202041220A (zh) 2020-11-16
PL2832359T3 (pl) 2019-04-30
JP6126041B2 (ja) 2017-05-10
AU2016201110B2 (en) 2017-06-15
KR20140136980A (ko) 2014-12-01
TW202015704A (zh) 2020-05-01
KR101536885B1 (ko) 2015-07-14
JP2013227291A (ja) 2013-11-07
PT2832359T (pt) 2019-01-29
SG11201405799TA (en) 2014-11-27
TR201820073T4 (tr) 2019-01-21
JP2022075813A (ja) 2022-05-18
AU2016201110A1 (en) 2016-03-10
US20200215093A1 (en) 2020-07-09
JP7042762B2 (ja) 2022-03-28
MX353874B (es) 2018-02-01
ES2702575T3 (es) 2019-03-04
CN113018259A (zh) 2021-06-25
AU2013241507A1 (en) 2014-10-09
KR101875845B1 (ko) 2018-07-06
TW201343196A (zh) 2013-11-01
TWI757799B (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
IN2014DN08632A (fr)
PH12015500115B1 (en) Glucagon analogues
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
IN2012DN03312A (fr)
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
WO2014164285A3 (fr) Utilisation de lévocétirizine et de montelukast dans le traitement de la vascularite
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MY161032A (en) Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
SG10201909382UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
EA201492081A1 (ru) (r)-нифурател, его применение в лечении инфекций и синтез (r)- и (s)-нифуратела
MX2017015293A (es) Composicion para tratar lesiones tisulares.
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
NZ707081A (en) Agent for preventing or improving decline in brain function
EA033769B9 (ru) Отселектированный амид -гидроксимасляной кислоты и его применения при лечении злоупотребления алкоголем
PH12018501624A1 (en) A composition comprising pic for treatment of cancer
HK1198632A1 (en) Compositions comprising cimetidine and n,o-carboxymethyl chitosan for the prevention and therapy of pathologies of the skin and the mucous membranes and in the odontostomatological field no-
EP2886112A4 (fr) Composition contenant comme principe actif de la s-allyl-l-cystéine et destinée à prévenir ou à traiter des maladies oculaires, et formulation pharmaceutique contenant cette composition
PH12015500070B1 (en) Pediatric oral liquid compositions containing nepadutant
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag
TH157373A (th) สารละลายที่เกี่ยวกับตาที่ประกอบรวมด้วยไดควาโฟซอล